HSBC stock rises on Singapore insurance sale talk — here’s what investors are watching next
15 January 2026
2 mins read

HSBC stock rises on Singapore insurance sale talk — here’s what investors are watching next

London, January 15, 2026, 08:29 GMT — Regular session underway.

  • Shares in HSBC jumped roughly 0.9% during early London trading, following reports that the bank is considering its options for the Singapore insurance unit.
  • A Bloomberg report cited by Reuters suggests the unit might be worth over $1 billion.
  • Investors are keeping an eye on a Hong Kong court date linked to HSBC’s plan to buy out Hang Seng Bank, along with HSBC’s annual results due next month.

HSBC shares ticked up Thursday following reports that the bank is considering selling its Singapore insurance unit, fueling chatter around CEO Georges Elhedery’s overhaul efforts. The London-listed stock rose 0.9%, hitting 1,223.8 pence by 08:28 GMT. (Google)

This potential deal stands out as another step in HSBC’s drive to streamline and redeploy capital, despite positioning the market as central to its Asia wealth play. For equity investors, selling assets can suggest discipline—or spark new doubts about HSBC’s long-term holdings.

HSBC is weighing a potential sale of HSBC Life (Singapore), Bloomberg News reported Wednesday, citing insiders. Sources told Bloomberg the unit might fetch over $1 billion in a deal. (Reuters)

Sources close to the talks say HSBC, along with a financial adviser, is conducting a review. Other insurers and investment firms have expressed initial interest, but no final call has been reached. An HSBC spokesperson declined to address market rumors, reaffirming the bank’s commitment to Singapore as a key international wealth and wholesale center, The Business Times reported. (The Business Times)

HSBC’s insurance arm in Singapore offers a range of products like life and critical illness cover, savings plans, personal accident, and health policies, according to the report. The bank grew this segment partly via acquisitions, notably snapping up AXA Insurance in Singapore for $529 million in 2022, it noted.

UK lenders are also factoring in shifting rate expectations. On Wednesday, Bank of England rate-setter Alan Taylor said interest rates are “set to fall further” as inflation edges closer to the 2% target faster than anticipated. Markets have priced in two additional quarter-point cuts this year. (Reuters)

HSBC’s moves in Singapore will draw close attention, given the bank’s push to make the city a key regional wealth and corporate center. Selling assets there might unlock capital, but it risks cutting into offerings that help banks strengthen ties with wealthy clients.

Trading the headline carries clear risks. Strategic reviews often stall without deals, and if talks move forward, the final price might fall short once costs and regulatory challenges are factored in. The sale process could also stretch out, particularly if bidders challenge growth projections and company claims.

HSBC has another Asia deal advancing through the courts. Minority shareholders at Hang Seng Bank have approved HSBC’s bid to take the Hong Kong lender private. The High Court in Hong Kong is set to hold a hearing on January 23. If the court gives the green light, Hang Seng is likely to be delisted on January 27. “The approval reflects strong confidence in Hang Seng Bank’s franchise,” Elhedery said earlier. (Reuters)

HSBC’s annual results drop on February 25. Investors will be watching closely for updates on the Singapore review and more clarity on capital priorities for 2026. (Hsbc)

Stock Market Today

  • BridgeBio Pharma Valuation After Attruby Uptake, BBP-418 Data, and Late-Stage Pipeline Momentum
    January 15, 2026, 6:33 AM EST. BridgeBio Pharma (BBIO) has drawn fresh attention after reporting more than 6,600 prescriptions for its ATTR-CM therapy Attruby, releasing interim Phase 3 data for BBP-418, and outlining a new TTR amyloid depleter program. Our latest analysis notes a 90-day share-price gain of 41.6% and a 3-year total shareholder return, with the stock near US$77.90. The fair value estimate stands around US$84.65, implying upside if late-stage programs convert to revenue and earnings. Analysts' consensus price target is US$63.81, with a range from US$41.00 to US$95.00. Risks include durability of Attruby, negative trial data, and regulatory delays. Valuation shows BridgeBio trading at a discount to our fair value, but a high P/S ratio (~42.4x vs 26.8x fair). A premium valuation hinges on execution and margin expansion.
Standard Chartered stock rises as buyback rolls on; eyes on next results
Previous Story

Standard Chartered stock rises as buyback rolls on; eyes on next results

Lloyds share price nudges higher as Morgan Stanley flags UK bank upside ahead of Jan 29 results
Next Story

Lloyds share price nudges higher as Morgan Stanley flags UK bank upside ahead of Jan 29 results

Go toTop